Stay updated with breaking news from Cedric Ogorman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Company Well-Positioned for a Pivotal 2024 with Multiple Key Clinical Development Milestones Anticipated Relmada's Strong Balance Sheet to Support the Company Through All of 2024's Expected Critical...
By Colin Kellaher Relmada Therapeutics shares tumbled more than 25% Thursday after the late-stage biotechnology said its chief medical officer had left after...
Operator: Good afternoon, ladies and gentlemen. And welcome to Relmada Therapeutics, Inc. Third Quarter 2023 Earnings Conference Call. At this time, all lines are in listen-only mode.
/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...
Relmada Therapeutics, Inc. has announced rapid and sustained effects of an anti-depressant in patients with major depressive disorders (MDD).